About Bioatla (BCAB)
BioAtla, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
- USD0.40
- USD0.41
- USD0.36
- USD1.43
- -55.30%
- --
- 1.77M
- 1.60M
- 32M
- 0.24
- -35.70%
Stock News
2 hours ago
Trump says he’s ‘inclined to keep Exxon out’ of Venezuela after CEO’s skepticism
MarketWatch
yesterday
Here are the 3 big things we're watching in the stock market in the week ahead
CNBC
yesterday
ICE Minneapolis shooting: Noem calls Good's actions ‘domestic terrorism’
CNBC
yesterday
3 ways parents can lower kids' screentime, from the co-author of 'The Amazing Generation'
CNBC